|
Ondansetron drug commonly known as Zofran is used for treatment of
nausea and vomiting induced by chemotherapeutic treatment. Zofran
came into existence in 1984 at Glaxo's laboratories and several
clinical trials were undertaken before the company sent this pill
for FDA approval in 1986. Zofran was patented in the year 1987 under
U.S. patent protection program with U.S. Patent number 4695578.
It was not until the year 1991 that this fill manufactured by its
manufacturer Glaxo's laboratories was awarded FDA (Food and drug
administration) approval. Glaxo's laboratories did extensive
research along with various new clinical trials, due to this reason
the manufacturer was awarded patent extension though the term of
patent extension of this drug ended on December 26, 2006.
The first FDA approved generic version of Zofran came into existence
in December 2006 after series of clinical trials. The present
manufacturers of this pill are: GlaxoSmithKline (GSK) manufacturing
under the name of Zofran, Gedeon Richter Ltd. The sale of this drug
is under the name of Emetron. Cipla Ltd makes this pill under the
name of Emeset, Korea United Pharmaceuticals marketing Ondansetron
as Emodar.
Another player, Baxter Healthcare has got approval for the
production of another variant of Ondansetron viz the Ondansetron
injection. The constituents of injection Ondansetron will be of USP,
8 mg/50 mL including 32 mg/50 mL iso-osmotic sodium chloride
solution. As this drug is known to have side effects it is only
available through the prescription of qualified physician only. With
its powerful effects in shielding effects of chemotherapy, the
future of this drug seems quite bright.
|
